论文部分内容阅读
非小细胞肺癌(non-small cell lung cancer,NSCLC)是现今世界范围内最常见的恶性肿瘤之一。手术及化疗是其治疗的主要方法,研究和确定临床上NSCLC化疗敏感性预测的靶向分子和指标将有利于NSCLC患者的个体化治疗。该文就核苷酸切除修复交叉互补组1(excision repair cross complementation group 1,ERCC1)基因作为NSCLC化疗疗效预测指标的研究现状作一综述。
Non-small cell lung cancer (NSCLC) is one of the most common malignancies in the world today. Surgery and chemotherapy are the main methods for its treatment. It is helpful for the individualized treatment of patients with NSCLC to study and determine the target molecules and indexes of clinical NSCLC chemosensitivity prediction. This review summarizes the research status of excision repair cross complementation group 1 (ERCC1) gene as a predictor of response to NSCLC chemotherapy.